Cathepsin L is required for endothelial progenitor cell-induced neovascularization

Nature Medicine

Volumn 11, Issue 2, 2005, Pages 206-213

  Urbich, Carmen ^e   Heeschen, Christopher ^e   Aicher, Alexandra ^a   Sasaki, Ken Ichiro ^a   Bruhl, Thomas ^a   Farhadi, Mohammad R ^b   Vajkoczy, Peter ^b   Hofmann, Wolf K ^a   Peters, Christoph ^c   Pennacchio, Len A ^d   Abolmaali, Nasreddin D ^a   Chavakis, Emmanouil ^a   Reinheckel, Thomas ^c   Zeiher, Andreas M ^a   Dimmeler, Stefanie ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN L;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL INVASION; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HINDLIMB; HUMAN; HUMAN CELL; IN VITRO STUDY; ISCHEMIA; LIMB ISCHEMIA; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

ANIMALS; BIOLOGICAL MARKERS; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HINDLIMB; HUMANS; ISCHEMIA; MALE; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STEM CELLS;

EID: 20044373820     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1182     Document Type: Article

References (41)

1. Isner, J.M. & Asahara, T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 103, 1231-1236 (1999).
2. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31 (1995).
3. Risau, W. Mechanisms of angiogenesis. Nature 386, 671-674 (1997).
4. Carmeliet, P. & Jain, R.K. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
5. Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
6. Shi, Q. et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92, 362-367 (1998).
7. Kalka, C. et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. USA 97, 3422-3427 (2000).
8. Kawamoto, A. et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103, 634-647 (2001).
9. Assmus, B. et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106, 3009-3017 (2002).
10. Kocher, A.A. et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7, 430-436 (2001).
11. Joyce, J.A. et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453 (2004).
12. Berchem, G. et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21, 5951-5955 (2002).
13. Krueger, S., Kellner, U., Buehling, F. & Roessner, A. Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Ther. 8, 522-528 (2001).
14. Dimmeler, S. et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108, 391-397. (2001).
15. Vasa, M. et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ. Res. 89, E1-7 (2001).
16. Urbich, C. et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108, 2511-2516 (2003).
17. Fiebiger, E. et al. Invariant chain controls the activity of extracellular cathepsin L. J. Exp. Med. 196, 1263-1269 (2002).
18. Walker, B., Lynas, J.F., Meighan, M.A. & Bromme, D. Evaluation of dipeptide alpha-keto-beta-aldehydes as new inhibitors of cathepsin S. Biochem. Biophys. Res. Commun. 275, 401-405 (2000).
19. Li, Z. et al. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J. Biol. Chem. 279, 5470-5479 (2004).
20. Chauhan, S.S., Ray, D., Kane, S.E., Willingham, M.C. & Gottesman, M.M. Involvement of carboxy-terminal amino acids in secretion of human lysosomal protease cathepsin L. Biochemistry 37, 8584-8594 (1998).
21. Libby, P. & Schonbeck, U. Drilling for oxygen: angiogenesis involves proteolysis of the extracellular matrix. Circ. Res. 89, 195-197 (2001).
22. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 6, 389-395 (2000).
23. Devy, L. et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor I is dose dependent. FASEB J. 16, 147-154 (2002).
24. Rooprai, H.K. & McCormick, D. Proteases and their inhibitors in human brain tumours: a review. Anticancer Res. 17, 4151-4162 (1997).
25. Turk, V., Turk, B. & Turk, D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20, 4629-4633 (2001).
26. Stypmann, J. et al. Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc. Natl. Acad. Sci. USA 99, 6234-6239 (2002).
27. Tobin, D.J. et al. The lysosomal protease cathepsin L is an important regulator of keratinocyte and melanocyte differentiation during hair follicle morphogenesis and cycling. Am. J. Pathol. 160, 1807-1821 (2002).
28. Shi, G.P. et al. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 92, 493-500 (2003).
29. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201 (2001).
30. Rafii, S., Lyden, D., Benezra, R., Hattori, K. & Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer 2, 826-835 (2002).
31. Nakagawa, T. et al. Cathepsin L: critical role in li degradation and CD4 T cell selection in the thymus. Science 280, 450-453 (1998).
32. Roth, W. et al. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J. 14, 2075-2086 (2000).
33. Houseweart, M.K. et al. Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM 1). J. Neurobiol. 56, 315-327 (2003).
34. Saftig, P. et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 14, 3599-3608 (1995).
35. Lelongt, B. et al. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J. Exp. Med. 193, 793-802 (2001).
36. Urbich, C. et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin. FASEB J. 16, 706-708 (2002).
37. Premzl, A., Zavasnik-Bergant, V., Turk, V. & Kos, J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp. Cell. Res. 283, 206-214 (2003).
38. Aicher, A. et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat. Med. 9, 1370-1376 (2003).
39. Dennhofer, R. et al. Invasion of melanoma cells into dermal connective tissue in vitro: evidence for an important role of cysteine proteases. Int. J. Cancer 106, 316-323 (2003).
40. Kaberdin, V.R. & McDowall, K.J. Expanding the use of zymography by the chemical linkage of small, defined substrates to the gel matrix. Genome Res. 13, 1961-1965 (2003).
41. Hinds, K.A. et al. Highly efficient endosomal labeling of progenitor and stem cells with large magnetic particles allows magnetic resonance imaging of single cells. Blood 102, 867-872 (2003).